iBio initiates primate study for obesity antibody candidate IBIO-610

SAN DIEGO - iBio, Inc. (NASDAQ:IBIO), whose stock has seen a strong 49% return over the last month despite falling 60% in the past six months according to InvestingPro data, has begun a non-human primate study for its Activin E antibody candidate IBIO-610, the company announced in a press release Monday.

The preclinical study will evaluate the pharmacokinetics and early efficacy signals of IBIO-610 in obese and elderly non-human primates, with a focus on its effects on fat reduction and body composition. Initial data is expected by early fourth quarter, ahead of the company’s next earnings report scheduled for September 19.

The study follows production scale-up and preclinical mouse studies that showed IBIO-610 reduced fat by 26% and demonstrated synergistic effects when combined with GLP-1 therapy, where fat reduction increased to 77%.

Additional mouse study data to be presented at the American Diabetes Association’s Scientific Sessions on June 23 shows IBIO-610 drove an 8.9% overall body weight loss when used alone. The data also indicates the antibody can prevent weight regain following discontinuation of GLP-1 treatment in diet-induced obese mice.

"The promising preclinical data we’ve generated for this novel approach in the field of obesity are highly encouraging, especially regarding its ability to drive fat-selective weight loss and support long-term weight maintenance," said Martin Brenner, CEO and Chief Scientific Officer of iBio. The company, currently valued at $15.3 million, faces financial challenges with negative EBITDA of -$16 million in the last twelve months.InvestingPro analysis reveals 13 additional key insights about iBio’s financial health and market position. Subscribers can access detailed metrics and expert analysis to make informed investment decisions.

The company reported that IBIO-610 reduced subcutaneous fat by 31% when used alone, with this effect increasing to 74% reduction when combined with a GLP-1 receptor agonist.

iBio describes IBIO-610 as a "first-in-class" Activin E antibody. The development is part of the company’s program to create AI-guided antibody therapeutics for cardiometabolic conditions.

In other recent news, iBio, Inc. has secured approximately $6.2 million through a warrant exercise agreement with institutional investors. This transaction involves the issuance of over 5.6 million shares at a price of $1.11 each, with the proceeds intended for working capital and general corporate purposes. Additionally, the investors received new warrants to purchase up to approximately 11.25 million shares at $0.86 per share, exercisable over the next five years. In another development, iBio reported promising pharmacokinetics data for its experimental drug IBIO-600, an anti-myostatin antibody, indicating a potential extended half-life of up to 130 days in humans. This could allow for a dosing schedule of once every three to six months, which may reduce the dosing burden for patients. The company also announced encouraging preclinical data for its Activin E antibody, showing significant weight and body fat loss in obese mice. These developments highlight iBio’s ongoing efforts in advancing its cardiometabolic and obesity treatment pipeline. The company plans to submit a regulatory application for IBIO-600 in the first quarter of 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.